Market open
Standard BioTools/$LAB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Standard BioTools
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Ticker
$LAB
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
537
Website
LAB Metrics
BasicAdvanced
$588M
-
-$0.45
1.57
-
Price and volume
Market cap
$588M
Beta
1.57
52-week high
$3.04
52-week low
$1.21
Average daily volume
1.7M
Financial strength
Current ratio
3.761
Quick ratio
3.33
Long term debt to equity
5.812
Total debt to equity
18.285
Interest coverage (TTM)
-26.26%
Management effectiveness
Return on assets (TTM)
-14.69%
Return on equity (TTM)
-37.25%
Valuation
Price to revenue (TTM)
2.833
Price to book
1.2
Price to tangible book (TTM)
1.64
Price to free cash flow (TTM)
-2.974
Growth
Revenue change (TTM)
48.23%
Earnings per share change (TTM)
-53.45%
3-year revenue growth (CAGR)
4.42%
3-year earnings per share growth (CAGR)
-20.95%
What the Analysts think about LAB
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Standard BioTools stock.
LAB Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
LAB Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
LAB News
AllArticlesVideos
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue
GlobeNewsWire·2 weeks ago
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire·1 month ago
Standard BioTools Appoints Alex Kim as Chief Financial Officer
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Standard BioTools stock?
Standard BioTools (LAB) has a market cap of $588M as of January 30, 2025.
What is the P/E ratio for Standard BioTools stock?
The price to earnings (P/E) ratio for Standard BioTools (LAB) stock is 0 as of January 30, 2025.
Does Standard BioTools stock pay dividends?
No, Standard BioTools (LAB) stock does not pay dividends to its shareholders as of January 30, 2025.
When is the next Standard BioTools dividend payment date?
Standard BioTools (LAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Standard BioTools?
Standard BioTools (LAB) has a beta rating of 1.57. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.